Copyright © Inderes 2011 - present. All rights reserved.
Selskabsmeddelelse

Ortivus' Year-end Report, January - December 2022

Ortivus
Download udgivelse

Ortivus ends 2022 with a growth of 10% for the full year

Highlights October - December 2022

  • The Estonian Health Insurance Fund (Haigekassa) decided to award Telia Eesti, with Ortivus as a subcontractor, a contract for the supply of MobiMed ePR to the entire ambulance fleet of Estonia. The 5-year contract regards a Software As a Service (SaaS) solution and has an order value of 26 MSEK, with a corresponding value for five optional years.
  • Ortivus received an order from Jersey Ambulance Service regarding the delivery of MobiMed ePR to the region’s ambulance service. The order value is estimated to 3.8 MSEK and the contract duration is 3 years, with a possible extension for an additional two years. The service value in addition to the delivery is estimated to 2.3 MSEK for years 2-5.
  • Ortivus was awarded a contract for delivery of MobiMed ePR, including the navigation application MobiMed enRoute, to all ambulance vehicles in the Region Jönköpings län. The contract duration is 5 years with a possible extension of 5 years. The order value is estimated to 4.2 MSEK and an additional 4.2 MSEK upon contract extension.
  • Ortivus signed a strategic partnership agreement with the Spanish company ITURRI, who are an established supplier to sectors including but not limited to healthcare and defence.
  • Ortivus announces the launch of a Danish subsidiary, Ortivus MobiMed ApS.

Significant events after end of the period

  • Ortivus AB acquired approximately 10% of the Swedish technology company H&E Solutions AB, the developer of Evam - an operating system for emergency vehicles.

October - December 2022

  • Net sales amounted to 33.4 (22.6) MSEK.
  • The gross margin amounted to 39% (54%).
  • Profit after tax amounted to 0.2 (1.7) MSEK.
  • Earnings after tax per share before and after dilution amounted to 0.00 (0.04) SEK.
  • Operating cash flow before changes in working capital amounted to 1.9 (3.2) MSEK.

January - December 2022

  • Net sales amounted to 104.5 (94.3) MSEK.
  • The gross margin amounted to 47% (51%).
  • Profit after tax amounted to 5.9 (9.2) MSEK.
  • Earnings after tax per share before and after dilution amounted to 0.13 (0.21) SEK.
  • Operating cash flow before changes in working capital amounted to -6.9 (14.7) MSEK.

Okt-Dec 2022Okt-Dec 2021Jan-Dec 2022Jan-Dec 2021
Net sales (MSEK)33.422.6104.594.3
Gross margin (%)39%54%47%51%
Operating profit (MSEK)0.31.75.89.3
Operating margin (%)1%8%6%10%
EBITDA (MSEK)1.13.110.212.7

Contacts

For further information, please contact

Reidar Gårdebäck, CEO

Telefon +46 8 446 45 00

About Ortivus

Ortivus develops and commercialises MobiMed, e-health and medical technology solutions for a safer and more efficient healthcare. The company was founded in 1985 and is today a leading provider of mobile digital solutions for prehospital care, worldwide. Ortivus' innovations are based on in-depth expertise in cardiology as well as decades of development together with users and customers. The company's headquarters are located in Danderyd, Stockholm. The company has, since 1998, a wholly owned subsidiary based in the United Kingdom and since 2022, a wholly owned subsidiary based in Denmark.

MobiMed is a modular platform that connects and enable real-time information sharing throughout the prehospital care chain. It is currently used by over 12,000 paramedics in over 2,700 emergency vehicles. The platform, MobiMed, consists of several product modules that are completely integrated but can also be used stand-alone. MobiMed comprises four main solutions: MobiMed Monitor, that measures, monitors and shares patients' vital parameters and ECG in real-time, MobiMed ePR, - an electronic patient record for decision support, collection of patient data and clinical documentation, MobiMed enRoute, - a tool for navigation and case management, and MobiMed Life - a range of stand-alone defibrillators.

MobiMed saves vital seconds and enable healthcare professionals make the right decisions in critical situations. MobiMed also contributes to improved quality of care and saved resources.

Ortivus Class A and Class B shares are listed on the NASDAQ Stockholm Small Cap list.
 
Read more about Ortivus at www.ortivus.com

This information is information that Ortivus is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-02-17 08:30 CET.

Attachments

Ortivus Year End Report January December 2022

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.